|   From the Trenches

Goldilocks And GMP

New therapeutic platforms, like those based on cell and gene therapy, provide potential to address diseases in new ways and hold tremendous promise for alleviating human suffering.  Despite this, progress often reaches a critical juncture when attempts are made to scale manufacturing from research to late-stage clinical trials and commercialization.

This blog was written by Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.